TABLE 3-9 Nefazodone

Study

Populationa

Arm (N)

Handling of Dropouts and % Completed Tx by Arm

PTSD Outcome Measure

Davis et al., 2004

Male, combat

Total (42)

LOCF

CAPS-Total

Nefazodone (27)

52%

PL (15)

60%

aIn the population column, male alone or female alone denotes that at least 80% of the study population was male or female. If only one trauma type is listed, at least 80% of the study population reported that type of trauma.

bPTSD outcome measure change data were obtained either directly from the study, when

TABLE 3-10 Venlaflaxine

Study

Populationa

Arm (N)

Handling of Dropouts and % Completed Tx by Arm

PTSD Outcome Measure

Davidson et al., 2006a

Male and Female, mixed trauma (12% combat)

Total (329)

LOCF

CAPS-SX

Venlaflaxine (161)

70%

PL (168)

67%

Davidson et al., 2006b

Male and Female, S&NS abuse, 9% combat

Total (538)c

LOCF and observed cases analysis are endpoint 65% overall

CAPS-SX

Venlafaxine (179)

Sertalined (173)

NR

PL (179)

NR

 

NR

aIn the population column, male alone or female alone denotes that at least 80% of the study population was male or female. If only one trauma type is listed, at least 80% of the study population reported that type of trauma.

bPTSD outcome measure change data were obtained either directly from the study, when provided, or by subtracting data reported at treatment completion (not follow-up data) from

with a placebo control and a crossover study design. Treatment lasted 4 weeks, and the study did not have post-treatment follow-up. The PTSD outcome measure used in this study was IES (Kaplan et al., 1996).

The studies of inositol and cycloserine were small, used a weak crossover design, and failed to show improvement in overall PTSD measures (Heresco-Levy et al., 2002; Kaplan et al., 1996).



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement